Research programme: amyotrophic lateral sclerosis gene therapy - Gene Therapy Research Institution

Drug Profile

Research programme: amyotrophic lateral sclerosis gene therapy - Gene Therapy Research Institution

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gene Therapy Research Institution
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 11 Aug 2017 Preclinical trials in Amyotrophic lateral sclerosis in Japan (IV) (Gene Therapy Research Institution pipeline, August 2017)
  • 11 Aug 2017 Pharmacodynamics and adverse events data from a preclinical study in Amyotrophic lateral sclerosis released by Gene Therapy Research Institution (Gene Therapy Research Institution website, August 2017)
  • 11 Aug 2017 Gene Therapy Research Institution plans phase I/II trials in 2019 (Gene Therapy Research Institution pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top